Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autogenous bone graft-Cairo University refers to a surgical treatment modality being evaluated as a control arm in clinical trials at Cairo University (notably NCT05445102) for the management of periodontal intrabony defects. This biologic intervention involves harvesting bone tissue from the patient's own body—specifically from the retromolar area using an automatic chip maker (ACM) bur—and processing it into particles using a hand bone mill. The graft is then implanted into periodontal defects using a modified minimally invasive surgical technique (M-MIST). As an autologous tissue, it provides a gold-standard combination of osteogenic properties (living bone-forming cells), osteoinductive properties (growth factors like bone morphogenetic proteins), and osteoconductive properties (a physical scaffold for new bone growth), aiming to regenerate lost alveolar bone and periodontal attachment in patients with periodontitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autogenous bone graft-Cairo University.